Urogen Pharma (URGN) Competitors $18.87 +0.77 (+4.25%) Closing price 04:00 PM EasternExtended Trading$18.54 -0.34 (-1.78%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock URGN vs. LNTH, AKRO, CRNX, APLS, TLX, ZLAB, KYMR, AMRX, CNTA, and RAREShould you be buying Urogen Pharma stock or one of its competitors? The main competitors of Urogen Pharma include Lantheus (LNTH), Akero Therapeutics (AKRO), Crinetics Pharmaceuticals (CRNX), Apellis Pharmaceuticals (APLS), Telix Pharmaceuticals (TLX), Zai Lab (ZLAB), Kymera Therapeutics (KYMR), Amneal Pharmaceuticals (AMRX), Centessa Pharmaceuticals (CNTA), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry. Urogen Pharma vs. Its Competitors Lantheus Akero Therapeutics Crinetics Pharmaceuticals Apellis Pharmaceuticals Telix Pharmaceuticals Zai Lab Kymera Therapeutics Amneal Pharmaceuticals Centessa Pharmaceuticals Ultragenyx Pharmaceutical Urogen Pharma (NASDAQ:URGN) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability. Which has better valuation & earnings, URGN or LNTH? Lantheus has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUrogen Pharma$90.40M9.66-$126.87M-$3.32-5.68Lantheus$1.52B2.31$312.44M$3.7613.71 Is URGN or LNTH more profitable? Lantheus has a net margin of 17.82% compared to Urogen Pharma's net margin of -164.44%. Lantheus' return on equity of 34.06% beat Urogen Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Urogen Pharma-164.44% -97,487.15% -59.38% Lantheus 17.82%34.06%19.10% Do insiders and institutionals have more ownership in URGN or LNTH? 91.3% of Urogen Pharma shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 4.7% of Urogen Pharma shares are owned by company insiders. Comparatively, 1.5% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor URGN or LNTH? In the previous week, Lantheus had 58 more articles in the media than Urogen Pharma. MarketBeat recorded 65 mentions for Lantheus and 7 mentions for Urogen Pharma. Urogen Pharma's average media sentiment score of 0.92 beat Lantheus' score of 0.18 indicating that Urogen Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Urogen Pharma 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 12 Very Positive mention(s) 1 Positive mention(s) 40 Neutral mention(s) 4 Negative mention(s) 3 Very Negative mention(s) Neutral Which has more volatility and risk, URGN or LNTH? Urogen Pharma has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.15, indicating that its share price is 85% less volatile than the S&P 500. Do analysts recommend URGN or LNTH? Urogen Pharma presently has a consensus price target of $32.00, suggesting a potential upside of 69.58%. Lantheus has a consensus price target of $85.50, suggesting a potential upside of 65.83%. Given Urogen Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Urogen Pharma is more favorable than Lantheus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Urogen Pharma 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00Lantheus 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 SummaryLantheus beats Urogen Pharma on 9 of the 17 factors compared between the two stocks. Get Urogen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding URGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart URGN vs. The Competition Export to ExcelMetricUrogen PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$872.93M$3.14B$5.81B$10.36BDividend YieldN/A2.37%5.86%4.62%P/E Ratio-5.6821.3676.8726.99Price / Sales9.66248.62449.2288.69Price / CashN/A45.4837.2260.63Price / Book-89.869.6913.836.37Net Income-$126.87M-$52.92M$3.29B$271.46M7 Day Performance-1.97%1.44%0.94%2.34%1 Month Performance-2.73%6.02%5.31%7.77%1 Year Performance44.05%12.89%84.25%31.08% Urogen Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)URGNUrogen Pharma4.1069 of 5 stars$18.87+4.3%$32.00+69.6%+41.0%$872.93M$90.40M-5.68200LNTHLantheus4.5492 of 5 stars$52.59-4.5%$91.60+74.2%-51.8%$3.57B$1.53B13.98700Trending NewsAnalyst ForecastAnalyst RevisionAKROAkero Therapeutics3.9091 of 5 stars$43.53-2.4%$81.14+86.4%+58.3%$3.48BN/A-21.7730Gap UpCRNXCrinetics Pharmaceuticals3.8822 of 5 stars$35.69-2.2%$68.86+93.0%-35.5%$3.36B$1.39M-8.69210Positive NewsAPLSApellis Pharmaceuticals4.1763 of 5 stars$26.41-1.6%$34.12+29.2%-34.9%$3.34B$754.65M-14.51770Positive NewsAnalyst RevisionTLXTelix Pharmaceuticals3.8173 of 5 stars$9.69+4.3%$21.33+120.3%N/A$3.28B$516.72M0.00N/AAnalyst ForecastHigh Trading VolumeZLABZai Lab3.2914 of 5 stars$28.82-8.5%$56.35+95.6%+56.9%$3.22B$398.99M-14.141,869KYMRKymera Therapeutics1.9569 of 5 stars$43.78+0.7%$58.76+34.2%+1.7%$3.13B$44.71M-12.60170Trending NewsAnalyst ForecastInsider TradeGap UpAMRXAmneal Pharmaceuticals3.3856 of 5 stars$9.90+0.1%$11.60+17.2%+8.8%$3.11B$2.79B990.498,100Positive NewsAnalyst ForecastCNTACentessa Pharmaceuticals3.1734 of 5 stars$22.76+9.2%$31.45+38.2%+34.2%$3.05B$6.85M-12.73200Insider TradeHigh Trading VolumeRAREUltragenyx Pharmaceutical4.3147 of 5 stars$31.57+0.2%$81.50+158.2%-50.9%$3.04B$560.23M-5.701,294Positive News Related Companies and Tools Related Companies Lantheus Competitors Akero Therapeutics Competitors Crinetics Pharmaceuticals Competitors Apellis Pharmaceuticals Competitors Telix Pharmaceuticals Competitors Zai Lab Competitors Kymera Therapeutics Competitors Amneal Pharmaceuticals Competitors Centessa Pharmaceuticals Competitors Ultragenyx Pharmaceutical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:URGN) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Urogen Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share Urogen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free URGN Stock Alerts